LIVIVO - Search results -

Search results

Result 1 - 10 of total 231

Search options

Book ; Online: Kultur unterwegs: Relevanz einer Instanz : Reisebilder, Dingwelten, Perspektiven

Schleper, Thomas / Steinert, Mark / Karabaic, Milena / Veltzke, Veit / Otten, Thomas / Valk, Thorsten / Käss, Alexandra / Mentzel, Jan-David / Mangold, Josef / Hauser, Walter / Hänel, Dagmar / Kleefeld, Klaus-Dieter / Bredenbeck, Martin

2021

Keywords	The arts: general issues ; Bildung, Denkmalpflege, Digitalität, Industriekultur, Krise, Kulturarbeit, Kulturlandschaft, Kunst, Museum, Nachhaltigkeit, Popularkultur, Strukturwandel, Tourismus, Wissenschaft
Size	1 electronic resource (224 pages)
Publisher	Reimer Verlag
Publishing place	Berlin
Document type	Book ; Online
Note	German ; Open Access
HBZ-ID	HT021233084
ISBN	978-3-98501-066-0 ; 978-3-7861-2880-9 ; 3-98501-066-8 ; 3-7861-2880-4
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book ; Online: Green bridges, wildlife tunnels and fauna culverts

Reck, Heinrich / Hänel, Kersten / Strein, Martin / Georgii, Bertram / Henneberg, Michael / Peters-Ostenberg, Elke / Böttcher, Marita

the biodiversity approach : executive summary of the research + development project "BfN-defragmentation handbook" (FKZ 3511 82 1200) = Grünbrücken, Faunatunnel und Tierdurchlässe : Anforderungen an Querungshilfen : Praxisempfehlungen aus dem F+E-Vorhaben "Handbuch Wiedervernetzung" (FKZ 3511 82 1200)

(BfN-Skripten ; 522)

2019

Title variant	Grünbrücken, Faunatunnel und Tierdurchlässe
Institution	Deutschland / Bundesamt für Naturschutz
Author's details	Heinrich Reck, Kersten Hänel, Martin Strein, Bertram Georgii, Michael Henneberg, Elke Peters-Ostenberg, Marita Böttcher ; BfN, Federal Agency for Nature Conservation
Series title	BfN-Skripten ; 522 BfN-Skripten / Bundesamt für Naturschutz
Collection	BfN-Skripten / Bundesamt für Naturschutz
Language	German ; English
Size	1 Online-Ressource (98 Seiten), Illustrationen, Diagramme, Karten
Publisher	Bundesamt für Naturschutz
Publishing place	Bonn-Bad Godesberg
Publishing country	Germany
Document type	Book ; Online
HBZ-ID	HT020003205
ISBN	9783896242594 ; 3896242598
DOI	10.19217/skr522
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Full text online

Full text

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany.

Sauer, Sandra / Engelhardt, Monika / Trautmann-Grill, Karolin / Kimmich, Christoph / Hänel, Mathias / Schmidt-Hieber, Martin / Salwender, Hans / Flossmann, Carmen / Heckmann, Hiltrud / Ertel, Franziska / Friederich, Andrea / Patel, Sachin / Thun, Barbara / Raab, Marc S

Bone marrow transplantation

2024

Abstract: There are limited data guiding choice of re-induction therapies for patients with relapsed/refractory multiple myeloma (RRMM) prior to stem cell transplantation (SCT). We performed a retrospective medical chart review of 171 patients with RRMM in Germany ...

Abstract	There are limited data guiding choice of re-induction therapies for patients with relapsed/refractory multiple myeloma (RRMM) prior to stem cell transplantation (SCT). We performed a retrospective medical chart review of 171 patients with RRMM in Germany who received re-induction therapy in second line (78%; n = 134) or third line (22%; n = 37) prior to re-SCT. Index therapy was defined as first completed re-induction therapy for planned myeloablative conditioning and SCT in second/third line within the eligibility period (1/2016-12/2019). Most common pre-index first line and maintenance therapy used were bortezomib-based combinations (91%; n = 155/171) and lenalidomide (55%; n = 29/53), respectively. Median duration of index therapy line was 9 months; carfilzomib-based combinations were the most widely used in second/third line re-induction therapy (49%; n = 83/171), followed by daratumumab-based combinations (21%; n = 36/171). Overall response rates in second/third line were 87% after re-induction and 96% after SCT; median time to next treatment line after start of index therapy was 31 months; median progression-free survival (PFS) was 29 months; and median overall survival after index date was not reached. Based on these data, re-induction therapy with salvage SCT appears to be beneficial in selected patients with RRMM in clinical practice in Germany, translating into deep responses, long PFS and prolonged time to next treatment.
Language	English
Publishing date	2024-03-14
Publishing country	England
Document type	Journal Article
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-024-02208-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Correction: Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow‑up of 14.4 years.

Kürzel, Sabine / Blaudszun, André-René / Stahl, Lilly / Herbst, Regina / Kroschinsky, Frank / Birkmann, Josef / Hänel, Annette / Schaefer-Eckart, Kerstin / Ehninger, Gerhard / Fiedler, Friedrich / Bornhäuser, Martin / Fricke, Stephan / Hänel, Mathias

Journal of cancer research and clinical oncology

2022 Volume 149, Issue 2, Page(s) 929–931

Language	English
Publishing date	2022-09-19
Publishing country	Germany
Document type	Published Erratum
ZDB-ID	134792-5
ISSN	1432-1335 ; 0171-5216 ; 0084-5353 ; 0943-9382
ISSN (online)	1432-1335
ISSN	0171-5216 ; 0084-5353 ; 0943-9382
DOI	10.1007/s00432-022-04324-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.10: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.

Journal of cancer research and clinical oncology

2021 Volume 148, Issue 5, Page(s) 1171–1181

Abstract: Purpose: The aim of this study was to prospectively compare the MIFAP protocol, which had been shown to be effective in patients with relapsed and refractory Hodgkin's lymphoma (HL) or aggressive non-Hodgkin's lymphoma (NHL), to an established regimen ... ...

Abstract	Purpose: The aim of this study was to prospectively compare the MIFAP protocol, which had been shown to be effective in patients with relapsed and refractory Hodgkin's lymphoma (HL) or aggressive non-Hodgkin's lymphoma (NHL), to an established regimen like Dexa-BEAM. Methods: Seventy-three adult patients with HL (N = 25) or aggressive NHL (N = 48) suffering from relapse or refractory disease were randomly allocated to receive two cycles of Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan; N = 37) or MIFAP (mitoxantrone, fludarabine, cytarabine, cisplatin; N = 36) prior to a consolidating high-dose therapy and hematopoietic cell transplantation (HCT). Primary endpoint was the overall response rate (ORR) [complete response (CR) and partial response (PR)] after two courses of salvage chemotherapy. Results: The ORR was 51% (CR 38%) and 53% (CR 36%) in the Dexa-BEAM arm and in the MIFAP arm (both not significant), respectively. There was a significantly higher grade 3-4 toxicity after MIFAP compared to Dexa-BEAM. Thirty-five patients were consolidated by autologous (N = 29), allogeneic (N = 1) or sequential autologous/allogeneic (N = 5) HCT. No significant differences were found in progression-free survival (PFS) and overall survival (OS) between the Dexa-BEAM and the MIFAP arms. Conclusion: Compared to Dexa-BEAM, MIFAP is associated with a higher toxicity and does not improve the outcome of patients with recurrent HL or aggressive NHL. For those patients, innovative treatment concepts like recently developed immunotherapies are necessary. Trial registration number: EudraCT number 2021-001937-38. Date of registration: 7 April 2021, retrospectively registered.
MeSH term(s)	Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carmustine/adverse effects ; Cytarabine ; Dexamethasone ; Etoposide/adverse effects ; Follow-Up Studies ; Hodgkin Disease/drug therapy ; Hodgkin Disease/pathology ; Humans ; Lymphoma/drug therapy ; Lymphoma, Non-Hodgkin ; Melphalan ; Neoplasm Recurrence, Local/drug therapy ; Prospective Studies ; Salvage Therapy/methods
Chemical Substances	Cytarabine (04079A1RDZ) ; Etoposide (6PLQ3CP4P3) ; Dexamethasone (7S5I7G3JQL) ; Melphalan (Q41OR9510P) ; Carmustine (U68WG3173Y)
Language	English
Publishing date	2021-06-26
Publishing country	Germany
Document type	Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
ZDB-ID	134792-5
ISSN	1432-1335 ; 0171-5216 ; 0084-5353 ; 0943-9382
ISSN (online)	1432-1335
ISSN	0171-5216 ; 0084-5353 ; 0943-9382
DOI	10.1007/s00432-021-03702-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.10: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.

Jaramillo, Sonia / Le Cornet, Lucian / Kratzmann, Markus / Krisam, Johannes / Görner, Martin / Hänel, Mathias / Röllig, Christoph / Wass, Maxi / Scholl, Sebastian / Ringhoffer, Mark / Reichart, Alexander / Steffen, Björn / Kayser, Sabine / Mikesch, Jan-Henrik / Schaefer-Eckart, Kerstin / Schubert, Jörg / Geer, Thomas / Martin, Sonja / Kieser, Meinhard /

Sauer, Tim / Kriegsmann, Katharina / Hundemer, Michael / Serve, Hubert / Bornhäuser, Martin / Müller-Tidow, Carsten / Schlenk, Richard F

Trials

2023 Volume 24, Issue 1, Page(s) 591

Abstract: Background: About 50% of older patients with acute myeloid leukemia (AML) fail to attain complete remission (CR) following cytarabine plus anthracycline-based induction therapy. Salvage chemotherapy regimens are based on high-dose cytarabine (HiDAC), ... ...

Abstract	Background: About 50% of older patients with acute myeloid leukemia (AML) fail to attain complete remission (CR) following cytarabine plus anthracycline-based induction therapy. Salvage chemotherapy regimens are based on high-dose cytarabine (HiDAC), which is frequently combined with mitoxantrone (HAM regimen). However, CR rates remain low, with less than one-third of the patients achieving a CR. FLT3-ITD has consistently been identified as an unfavorable molecular marker in both relapsed and refractory (r/r)-AML. One-quarter of patients who received midostaurin are refractory to induction therapy and relapse rate at 2 years exceeds 40%. The oral second-generation bis-aryl urea tyrosine kinase inhibitor quizartinib is a very selective FLT3 inhibitor, has a high capacity for sustained FLT3 inhibition, and has an acceptable toxicity profile. Methods: In this multicenter, upfront randomized phase II trial, all patients receive quizartinib combined with HAM (cytarabine 3g/m Conclusion: Currently, there is no commonly accepted standard for salvage chemotherapy treatment. The objective of the salvage therapy is to reduce leukemic burden, achieve the best possible remission, and perform a hemopoietic stem-cell transplantation. Thus, in patients with FLT3-ITD mutation, the comparison of quizartinib with intensive salvage therapy versus chemotherapy alone appears as a logical consequence in terms of efficacy and safety. Ethics and dissemination: Ethical approval and approvals from the local and federal competent authorities were granted. Trial results will be reported via peer-reviewed journals and presented at conferences and scientific meetings. Trial registration: ClinicalTrials.gov NCT03989713; EudraCT Number: 2018-002675-17.
MeSH term(s)	Humans ; Mitoxantrone/adverse effects ; Leukemia, Myeloid, Acute/drug therapy ; Phenylurea Compounds/adverse effects ; Chronic Disease ; Cytarabine/adverse effects ; fms-Like Tyrosine Kinase 3/genetics
Chemical Substances	Mitoxantrone (BZ114NVM5P) ; quizartinib (7LA4O6Q0D3) ; Phenylurea Compounds ; Cytarabine (04079A1RDZ) ; FLT3 protein, human (EC 2.7.10.1) ; fms-Like Tyrosine Kinase 3 (EC 2.7.10.1)
Language	English
Publishing date	2023-09-15
Publishing country	England
Document type	Randomized Controlled Trial ; Multicenter Study ; Clinical Trial, Phase II ; Journal Article
ZDB-ID	2040523-6
ISSN	1745-6215 ; 1468-6694 ; 1745-6215
ISSN (online)	1745-6215
ISSN	1468-6694 ; 1745-6215
DOI	10.1186/s13063-023-07421-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Point Mutations in the

Stasik, Sebastian / Kramer, Michael / Zukunft, Sven / Röllig, Christoph / Baldus, Claudia D / Platzbecker, Uwe / Serve, Hubert / Müller-Tidow, Carsten / Schäfer-Eckart, Kerstin / Kaufmann, Martin / Krause, Stefan / Sauer, Tim / Hänel, Mathias / Neubauer, Andreas / Ehninger, Gerhard / Bornhäuser, Martin / Schetelig, Johannes / Middeke, Jan M / Thiede, Christian

Frontiers in oncology

2022 Volume 12, Page(s) 862991

Abstract: ... ...

Abstract	FLT3
Language	English
Publishing date	2022-03-21
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2022.862991
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma

Kürzel, Sabine / Blaudszun, André-René / Stahl, Lilly / Herbst, Regina / Krochinsky, Frank / Birkmann, Josef / Hänel, Annette / Schäfer-Eckart, Kerstin / Ehninger, Gerhard / Fiedler, Friedrich / Bornhäuser, Martin / Fricke, Stephan / Hänel, Mathias

A prospective randomized multicenter phase II trial with a median follow-up of 14.4 years

2022

Abstract: 1171 ... 1181 ... Purpose: The aim of this study was to prospectively compare the MIFAP protocol, which had been shown to be effective in patients with relapsed and refractory Hodgkin's lymphoma (HL) or aggressive non-Hodgkin's lymphoma (NHL), to an ... ...

Abstract	1171 1181 Purpose: The aim of this study was to prospectively compare the MIFAP protocol, which had been shown to be effective in patients with relapsed and refractory Hodgkin's lymphoma (HL) or aggressive non-Hodgkin's lymphoma (NHL), to an established regimen like Dexa-BEAM. Methods: Seventy-three adult patients with HL (N = 25) or aggressive NHL (N = 48) suffering from relapse or refractory disease were randomly allocated to receive two cycles of Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan; N = 37) or MIFAP (mitoxantrone, fludarabine, cytarabine, cisplatin; N = 36) prior to a consolidating high-dose therapy and hematopoietic cell transplantation (HCT). Primary endpoint was the overall response rate (ORR) [complete response (CR) and partial response (PR)] after two courses of salvage chemotherapy. Results: The ORR was 51% (CR 38%) and 53% (CR 36%) in the Dexa-BEAM arm and in the MIFAP arm (both not significant), respectively. There was a significantly higher grade 3-4 toxicity after MIFAP compared to Dexa-BEAM. Thirty-five patients were consolidated by autologous (N = 29), allogeneic (N = 1) or sequential autologous/allogeneic (N = 5) HCT. No significant differences were found in progression-free survival (PFS) and overall survival (OS) between the Dexa-BEAM and the MIFAP arms. Conclusion: Compared to Dexa-BEAM, MIFAP is associated with a higher toxicity and does not improve the outcome of patients with recurrent HL or aggressive NHL. For those patients, innovative treatment concepts like recently developed immunotherapies are necessary. Trial registration number: EudraCT number 2021-001937-38. Date of registration: 7 April 2021, retrospectively registered. 148 5
Keywords	CAR-T-Zelle ; hematopoietic stem cell transplantation ; Hodgkin's lymphoma ; Non-Hodgkin's lymphoma ; salvage therapy ; 610 ; 616 ; 620
Subject code	610
Language	English
Publishing country	de
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Increased future occurrences of the exceptional 2018-2019 Central European drought under global warming.

Hari, Vittal / Rakovec, Oldrich / Markonis, Yannis / Hanel, Martin / Kumar, Rohini

Scientific reports

2020 Volume 10, Issue 1, Page(s) 12207

Abstract: Since the spring 2018, a large part of Europe has been in the midst of a record-setting drought. Using long-term observations, we demonstrate that the occurrence of the 2018-2019 (consecutive) summer drought is unprecedented in the last 250 years, and ... ...

Abstract	Since the spring 2018, a large part of Europe has been in the midst of a record-setting drought. Using long-term observations, we demonstrate that the occurrence of the 2018-2019 (consecutive) summer drought is unprecedented in the last 250 years, and its combined impact on the growing season vegetation activities is stronger compared to the 2003 European drought. Using a suite of climate model simulation outputs, we underpin the role of anthropogenic warming on exacerbating the future risk of such a consecutive drought event. Under the highest Representative Concentration Pathway, (RCP 8.5), we notice a seven-fold increase in the occurrence of the consecutive droughts, with additional 40 ([Formula: see text]) million ha of cultivated areas being affected by such droughts, during the second half of the twenty-first century. The occurrence is significantly reduced under low and medium scenarios (RCP 2.6 and RCP 4.5), suggesting that an effective mitigation strategy could aid in reducing the risk of future consecutive droughts.
Language	English
Publishing date	2020-08-06
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-020-68872-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Evaluation of Evaporation from Water Reservoirs in Local Conditions at Czech Republic

Eva Melišová / Adam Vizina / Martin Hanel / Petr Pavlík / Petra Šuhájková

Hydrology, Vol 8, Iss 153, p

2021 Volume 153

Abstract: Evaporation is an important factor in the overall hydrological balance. It is usually derived as the difference between runoff, precipitation and the change in water storage in a catchment. The magnitude of actual evaporation is determined by the ... ...

Abstract	Evaporation is an important factor in the overall hydrological balance. It is usually derived as the difference between runoff, precipitation and the change in water storage in a catchment. The magnitude of actual evaporation is determined by the quantity of available water and heavily influenced by climatic and meteorological factors. Currently, there are statistical methods such as linear regression, random forest regression or machine learning methods to calculate evaporation. However, in order to derive these relationships, it is necessary to have observations of evaporation from evaporation stations. In the present study, the statistical methods of linear regression and random forest regression were used to calculate evaporation, with part of the models being designed manually and the other part using stepwise regression. Observed data from 24 evaporation stations and ERA5-Land climate reanalysis data were used to create the regression models. The proposed regression formulas were tested on 33 water reservoirs. The results show that manual regression is a more appropriate method for calculating evaporation than stepwise regression, with the caveat that it is more time consuming. The difference between linear and random forest regression is the variance of the data; random forest regression is better able to fit the observed data. On the other hand, the interpretation of the result for linear regression is simpler. The study introduced that the use of reanalyzed data, ERA5-Land products using the random forest regression method is suitable for the calculation of evaporation from water reservoirs in the conditions of the Czech Republic.
Keywords	evaporation ; water reservoir ; regression ; observed data ; ERA5-Land data ; R language ; Science ; Q
Subject code	310
Language	English
Publishing date	2021-10-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Your last searches

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED